E Fund Management’s BioXcel Therapeutics BTAI Stock Holding History

E Fund Management’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-664	Closed	-$71K	–	297
2023 Q2	$71K	Buy	+664	New	+$221K	0.01%	305

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

E Fund Management's BTAI Position: Q3 2023 in Review

E Fund Management sold out of BioXcel Therapeutics (BTAI) in Q3 2023, closing a stake of 664 shares — an estimated $71K sold.

E Fund Management first reported a position in BTAI in Q2 2023 and held it in 1 quarter. The position peaked at $71K in Q2 2023. 85 funds tracked by Wall St. Rank hold BTAI as of Q3 2023.

E Fund Management reported no remaining BioXcel Therapeutics position as of Q3 2023 after selling out during the quarter.
E Fund Management sold 664 BioXcel Therapeutics shares in Q3 2023, an estimated $71K.
E Fund Management first reported a position in BioXcel Therapeutics in Q2 2023 and held it in 1 quarter.
E Fund Management's BioXcel Therapeutics position peaked at $71K in Q2 2023.
85 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2023.

Based on E Fund Management's 13F filing for Q3 2023, filed 13 Nov 2023.